Title:Limited Competition: Adult Brain Tumor Clinical Trials Consortium (U01)

Contact:

Jeffrey Abrams, M.D.
Division of Cancer Treatment and Diagnosis
National Cancer Institute
6130 Executive Boulevard, EPN Room 7025, MSC 7436
Bethesda, MD 20892-7436 (for U.S. Postal Service Express or regular mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: (301) 496-2522
Fax: (301) 402-0557
E-mail: abramsj@mail.nih.gov

Objective of Project:

The overall objective of this limited competition RFA is to improve the development of new treatment agents for adults with brain tumors through continued support of a unique, multi-center adult brain tumor consortium.

Description of Project:

Currently, two consortia are funded: (i) NABTT (New Approaches to Brain Tumor Therapy) [U01CA062475 (Operations), Johns Hopkins University] and (ii) NABTC (North American Brain Tumor Consortium) [U01CA062399(Operations), University of California San Francisco]. This limited competition RFA solicits a single joint application from both NABTT and NABTC to continue their activities as a single entity. The consolidated Adult Brain Tumor Consortium will be responsible for timely conduct of Phase 1 and 2 studies that are essential to NCI’s overall clinical research program for adults with brain tumors. This Funding Opportunity Announcement is co-sponsored by the National Institute of Neurological Disorders and Stroke (NINDS). The goal of NINDS is to assure that sufficient support exists to incorporate selected imaging studies into Consortium. Specifically, NINDS is focused on encouraging development of non-invasive imaging tools across the spectrum of neurological diseases. The specific objectives for the Consortium will be: (a) to safely and efficiently introduce novel anticancer agents to complement other modalities (radiotherapy and surgery) in the conduct of Phase 1-2 trials for adult brain tumors; (b) to proactively foster collaborations with other NCI and NIH funded researchers in the field, especially NCI-funded brain tumor SPORES (Specialized Programs of Research Excellence) and NCI-funded Cooperative Groups; and (c) to incorporate pharmacokinetic and pharmacodynamic endpoints (including imaging and translational laboratory studies) as appropriate into Phase 1-2 studies to facilitate future development of new treatment approaches.